Tool Compounds Robustly Increase Turnover of an Artificial Substrate by Glucocerebrosidase in Human Brain LysatesZdenek Berger, Warren D. Hirst, Matthew F. Calabrese et al.|PLoS ONE|2015Cited by 15
P4–277: Evaluation of beta‐amyloid‐lowering efficacy of a novel BACE1 inhibitor in multiple speciesCharles E. Nolan, David Riddell, Kevin Atchison et al.|Alzheimer s & Dementia|2013Cited by 0
P4–291: Predicting <i>in vivo</i> BACE inhibitor efficacy: Are human iPS‐derived neurons superior?Christine Oborski, David Riddell, Sandra J. Engle et al.|Alzheimer s & Dementia|2013Cited by 0
P4–278: Clinical gamma‐secretase inhibitors (GSIs) alter beta‐amyloid 40/42 ratio in brain and show CSF beta‐amyloid rebound <i>in vivo</i>Charles E. Nolan, David Riddell, Leslie R. Pustilnik et al.|Alzheimer s & Dementia|2013Cited by 0
P1–109: Inhibition of BACE1 reduces beta‐amyloid 1–40 but not N‐terminal‐truncated beta‐amyloidKevin Atchison, David Riddell, ONeill Brian et al.|Alzheimer s & Dementia|2013Cited by 0